PDCD1 and melanoma: BioNTech’s phase 2 trial (NCT04526899) showed positive results, with BNT111 plus cemiplimab significantly improving the objective response rate (ORR) in patients with anti-PD-1-refractory/relapsed, unresectable stage III/IV melanoma.